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Liver transplantation for cholangiocarcinoma- a hammer to crack a very
tough nut?
This month’s HPB sees the much awaited publication of the Dublin experience of liver transplantation for
cholangiocarcinoma. The group followed the previously published Mayo protocol of treating patients with cholan-
giocarcinoma with brachytherapy, external beam radiotherapy and 5-fluorouracil. Patients who had no radiological
evidence of disease progression underwent laparotomy or laparoscopy and negative lymph node biopsy and ifthere
was no evidence of peritoneal dissemination were listed for transplantation. 27 patients entered the protocol and 20
progressed to transplantation, 6 of whom required a simultaneous pancreaticoduodenectomy. Hospital mortality
was 4/20 or 20% but thereafter survival was reasonable giving overall survival estimates of approximately 75% at
1 year and 60% at 3 years. Liver transplantation for cholangiocarcinoma is a major undertaking but in oncological
terms the results are very good. The present series found best outcomes in patients with a complete pathological
response to neoadjuvant therapy although it could be argued that such patients may have experienced prolonged
survival without transplantation. The authors highlight the difficulty in determining the presence or absence of
viable tumour in the liver after chemoradiotherapy. The Dublin series did not replicate the excellent results
previously published in similarly selected patients from the Mayo Clinic, however, there is increasing interest in the
use of liver transplantation for primary and metastatic disease including cholangiocarcinoma, neuroendocrine and
colorectal metastases. The availability of organs for transplantation remains a limiting factor but carefully designed
studies such as this, strengthen the case for extending indications for liver transplantation at least within the context
of a clinical trial.
Stephen J Wigmore
Lessons for those contemplating laparoscopic liver resection
Over the last decade, laparoscopic liver resection (LLR) gained popularity for many HPB surgeons as a viable
alternative to the traditional open approach. It remains a technically challenging procedure and has potential for
major morbidity and mortality for patients if not performed well. In this issue of HPB, Trosi et al. describe a large
series (n = 242) of patients undergoing LLR over an eight year period to identify risk factors for conversion to open
surgery. The time period studied included the author’s learning curve and provided data on the denominator of
liver resections from which this series was selected. The overall conversion rate was 6.4%. The annual proportion of
patients undergoing LLR increased from 18% to 53% by the end of the study period. Major Hepatectomy made up
just 17.4% of the series and those requiring vascular or biliary reconstruction were excluded. Of the 17 patients who
required conversion, nine were for bleeding, four for oncological concerns and one for gas embolism. On subse-
quent analysis, the only factors associated with conversion were lesions located in the posterior or superior
segments. In the ensuing discussion, the authors describe in detail why and how bleeding became a problem and was
subsequently managed. This is worthwhile reading for those surgeons contemplating a move to LLR. The report
raises several important issues for the HPB specialty. Firstly, moving to LLR is not an all or nothing phenomenon
- it is a graduated curve. For those who work in smaller units, this poses a major problem in how to start and get
up the learning curve quickly. Clearly in a major unit such as that described, there was a significant degree of patient
selection in the early years and even after eight years only 53% of patients met the criteria for LLR. Could remote
telesurgery be a solution for smaller units? Secondly, the ability to deal with major haemorrhage is an issue since
conversion to open operation may be associated with significant morbidity for the patient. Having a plan and
understanding the tips to avoid and subsequently deal with haemorrhage laparoscopically is a must for anyone
starting out.
Saxon Connor
Reading from the same sheet of music
Reported rates of positive resection margins vary widely after pancreaticoduodenectomy (PD) for pancreatic
adenocarcinoma (PDAC). Why is this so, and why does it matter? Most attribute it to inconsistent pathological
evaluation of the specimen, and not to surgical technique or patient selection. To evaluate the impact of precise
resection margin status (R0 or R1) on clinical outcome following PD for PDAC, Delpero and colleagues from France
performed a prospective multicenter trial which yielded 150 evaluable patients. Surgeons followed a PD quality
protocol that standardized extents of vascular disconnection, vascular resection and lymphadenectomy. Surgeons
also multicolor inked three precise resection margins, and pathologists abided by a standardized pathology protocol
(Leeds) and stratified inked margins by 0.5mm increments up to 2.0mm. The article is beautifully illustrated, and
provides deep univariate and multivariate analyses to link clinical outcomes to observed incremental margin status.
We learn which margins matter in terms of progression free survival, and which do not. We learn that the PV-SMVm
was the most frequently invaded margin, and that more margins were positive when PV-SMV resection was
performed. Perhaps our most valuable lesson is that surgical and pathological standardization were in fact achieved
across multiple centers, and that the results did matter. Correctly, the authors highlight the values of standardized
margin analysis in terms of future clinical trial design and evaluations of new adjuvant treatments. Let’s hope their
message is embraced.
Mark Callery
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